Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.

Sethi S, Fervenza FC.

Semin Nephrol. 2011 Jul;31(4):341-8. doi: 10.1016/j.semnephrol.2011.06.005. Review.

PMID:
21839367
2.

Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.

Licht C, Fremeaux-Bacchi V.

Thromb Haemost. 2009 Feb;101(2):271-8. Review.

PMID:
19190809
3.

Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.

Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ.

Clin J Am Soc Nephrol. 2011 May;6(5):1009-17. doi: 10.2215/CJN.07110810. Epub 2011 Mar 17.

4.

Histopathology of MPGN and C3 glomerulopathies.

Cook HT, Pickering MC.

Nat Rev Nephrol. 2015 Jan;11(1):14-22. doi: 10.1038/nrneph.2014.217. Epub 2014 Dec 2. Review.

PMID:
25447133
5.

Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F.

J Med Genet. 2007 Mar;44(3):193-9. Epub 2006 Oct 3.

6.

Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G.

Mol Immunol. 2016 Mar;71:131-42. doi: 10.1016/j.molimm.2016.01.010. Epub 2016 Feb 16.

PMID:
26895476
7.

Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Bomback AS, Appel GB.

Nat Rev Nephrol. 2012 Nov;8(11):634-42. doi: 10.1038/nrneph.2012.213. Epub 2012 Oct 2. Review.

PMID:
23026947
8.

Membranoprolferative glomerulonephritis - mechanisms and treatment.

Appel GB.

Contrib Nephrol. 2013;181:163-74. doi: 10.1159/000348635. Epub 2013 May 8. Review.

PMID:
23689578
10.

Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.

Sethi S, Nester CM, Smith RJ.

Kidney Int. 2012 Mar;81(5):434-41. doi: 10.1038/ki.2011.399. Epub 2011 Dec 7. Review.

11.

Idiopathic membranoproliferative glomerulonephritis: does it exist?

Fervenza FC, Sethi S, Glassock RJ.

Nephrol Dial Transplant. 2012 Dec;27(12):4288-94. doi: 10.1093/ndt/gfs288. Epub 2012 Jul 13. Review. Erratum in: Nephrol Dial Transplant. 2013 Apr;28(4):1059.

12.

Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.

Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, Fervenza FC.

Clin J Am Soc Nephrol. 2010 May;5(5):770-82. doi: 10.2215/CJN.06760909. Epub 2010 Feb 25.

13.

Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis.

Meri S, Koistinen V, Miettinen A, Törnroth T, Seppälä IJ.

J Exp Med. 1992 Apr 1;175(4):939-50.

15.

Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Leroy V, Fremeaux-Bacchi V, Peuchmaur M, Baudouin V, Deschênes G, Macher MA, Loirat C.

Pediatr Nephrol. 2011 Mar;26(3):419-24. doi: 10.1007/s00467-010-1734-4. Epub 2010 Dec 25.

PMID:
21188423
16.

Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease.

Vernon KA, Pickering MC, Cook T.

Contrib Nephrol. 2011;169:198-210. doi: 10.1159/000314775. Epub 2011 Jan 20.

PMID:
21252520
17.

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V.

Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63. Epub 2012 Mar 28.

18.

Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.

Hawfield A, Iskandar SS, Smith RJ.

Am J Kidney Dis. 2013 May;61(5):828-31. doi: 10.1053/j.ajkd.2012.11.045. Epub 2013 Feb 5. Review.

PMID:
23391537
19.

Serum terminal complement component levels in hypocomplementemic glomerulonephritides.

Clardy CW, Forristal J, Strife CF, West CD.

Clin Immunol Immunopathol. 1989 Mar;50(3):307-20.

PMID:
2917423
20.

Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.

Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Józsi M.

Mol Immunol. 2009 Sep;46(14):2801-7. doi: 10.1016/j.molimm.2009.05.018. Epub 2009 Jul 28. Review.

PMID:
19640589
Items per page

Supplemental Content

Write to the Help Desk